



26 October 2022

## ASX ANNOUNCEMENT

### 2022 Annual General Meeting – Results of Meeting

Set out below are the results of the 2022 Annual General Meeting (**AGM**) held earlier today. All resolutions put to the AGM were decided by a poll.

Item	Resolution	Result
2	Remuneration Report	Passed as an advisory resolution
3	Re-election of Dr Robert Graham AO	Passed as an ordinary resolution
4	Election of Ms Janet West AM	Passed as an ordinary resolution
5	Approval of 10% placement capacity under Listing Rule 7.1A	Resolution withdrawn prior to the meeting
6	Approval to issue securities under the Executive Share Plan	Passed as an ordinary resolution
7	Grant of Shares under the Executive Share Plan to Mr David Anderson	Passed as an ordinary resolution

In accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2 the results of the AGM are provided in the attached document.

**Authorised for release by the Company Secretary of ImpediMed Limited.**

### Contact Details

#### Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.



# IMPEDIMED LIMITED

# RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING  
Wednesday, 26 October, 2022

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Direct vote (as at proxy close):		Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	For	Against	Abstain **	
2	REMUNERATION REPORT	N	571,409,438 81.62%	46,396,718 6.63%	2,879,153 0.41%	1,500	76,866,093 10.98%	2,492,908 0.36%	651,406,210 93.02%	48,889,626 6.98%	1,500	Carried
3	RE-ELECTION OF DR ROBERT GRAHAM AO	NA	599,288,373 82.04%	18,402,291 2.52%	2,961,312 0.41%	34,833	109,115,036 14.94%	720,444 0.10%	716,704,197 97.40%	19,122,735 2.60%	34,833	Carried
4	ELECTION OF MRS JANET WEST AM	NA	617,610,397 84.55%	80,267 0.01%	2,961,312 0.41%	34,833	109,115,036 14.94%	720,444 0.10%	735,026,221 99.89%	800,711 0.11%	34,833	Carried
5	APPROVAL OF ADDITIONAL 10% CAPACITY TO ISSUE EQUITY SECURITIES UNDER ASX LISTING RULE 7.1A	NA	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN	WITHDRAWN
6	APPROVAL TO ISSUE SECURITIES UNDER THE EXECUTIVE SHARE PLAN	NA	617,474,303 87.78%	180,804 0.03%	3,030,202 0.43%	1,500	77,206,589 10.98%	5,510,905 0.78%	701,483,931 99.20%	5,691,709 0.80%	1,500	Carried
7	GRANT OF SHARES UNDER THE EXECUTIVE SHARE PLAN TO MR DAVID ANDERSON	NA	617,474,303 87.78%	180,804 0.03%	3,030,202 0.43%	1,500	77,632,057 11.04%	5,085,437 0.72%	701,909,399 99.26%	5,266,241 0.74%	1,500	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item